| Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
|---|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 261226 | Peak area normalized | male | diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 364191 | Peak area normalized | female | diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 402559 | Peak area normalized | female | diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 418444 | Peak area normalized | female | normoglycemic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 569331 | Peak area normalized | female | diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 790045 | Peak area normalized | male | diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 1156002 | Peak area normalized | female | diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 1881438 | Peak area normalized | female | diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 3325228 | Peak area normalized | male | pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | 3495245 | Peak area normalized | female | diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | Peak area normalized | female | diabetic | no neuropathy | |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | Peak area normalized | female | normoglycemic | Neuropathy | |
| Reversed phase NEGATIVE ION MODE | DOCOSAHEXAENOIC ACID (M-H)- | Peak area normalized | male | pre-diabetic | Neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|